109. Dirice E, Ng RWS, Martinez R et al (2017) Isoform-selective inhibitor of histone deacetylase
3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from
diabetes. J Biol Chem 292:17598–17608
110. Jia H, Wang Y, Morris CD et al (2016) The effects of pharmacological inhibition of histone
deacetylase 3 (HDAC3) in Huntington’s disease mice. PLoS One 11:e0152498
111. Usui T, Okada M, Mizuno W et al (2012) HDAC4 mediates development of hypertension via
vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol 302:
H1894–H1904
112. Choi SY, Ryu Y, Kee HJ et al (2015) Tubastatin A suppresses renal fibrosis via regulation of
epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol
72:130–140
113. Ferrari A, Fiorino E, Longo R et al (2017) Attenuation of diet-induced obesity and induction of
white fat browning with a chemical inhibitor of histone deacetylases. Int J Obes (Lond)
41:289–298
114. Choong CJ, Sasaki T, Hayakawa H et al (2016) A novel histone deacetylase 1 and 2 isoformspecific inhibitor alleviates experimental Parkinson’s disease. Neurobiol Aging 37:103–116
115. Conforti F, Davies ER, Calderwood CJ et al (2017) The histone deacetylase inhibitor,
romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget 8:48737–48754
116. Trifunović D, Arango-Gonzalez B, Comitato A et al (2016) HDAC inhibition in the cpfl1
mouse protects degenerating cone photoreceptors in vivo. Hum Mol Genet 25:4462–4472
117. Li Y, Zhao T, Liu B et al (2015) Inhibition of histone deacetylase 6 improves long-term
survival in a lethal septic model. J Trauma Acute Care Surg 78:378–385
118. Pfaller MA, Messer SA, Georgopapadakou N et al (2009) Activity of MGCD290, a Hos2
histone deacetylase inhibitor, in combination with azole antifungals against opportunistic
fungal pathogens. J Clin Microbiol 47:3797–3804
119. Kuchler K, Jenull S, Shivarathri R et al (2016) Fungal KATs/KDACs: a new highway to better
antifungal drugs? PLoS Pathog 12:e1005938
120. Hailu GS, Robaa D, Forgione M et al (2017) Lysine deacetylase inhibitors in parasites: past,
present, and future perspectives. J Med Chem 60:4780–4804
121. Sumanadasa SD, Goodman CD, Lucke AJ et al (2012) Antimalarial activity of the anticancer
histone deacetylase inhibitor SB939. Antimicrob Agents Chemother 56:3849–3856
122. Chua MJ, Arnold MS, Xu W et al (2017) Effect of clinically approved HDAC inhibitors on
Plasmodium, Leishmania and Schistosoma parasite growth. Int J Parasitol Drugs Drug Resist
7:42–50
123. Ontoria JM, Paonessa G, Ponzi S et al (2016) Discovery of a selective series of inhibitors of
Plasmodium falciparum HDACs. ACS Med Chem Lett 7:454–459
124. Heimburg T, Chakrabarti A, Lancelot J et al (2016) Structure-based design and synthesis of
novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis. J Med Chem 59:2423–2435
125. Meyners C, Wolff B, Kleinschek A et al (2017) Perfluorinated hydroxamic acids are potent
and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa. Bioorg Med
Chem Lett 27:1508–1512
Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery
27
3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from
diabetes. J Biol Chem 292:17598–17608
110. Jia H, Wang Y, Morris CD et al (2016) The effects of pharmacological inhibition of histone
deacetylase 3 (HDAC3) in Huntington’s disease mice. PLoS One 11:e0152498
111. Usui T, Okada M, Mizuno W et al (2012) HDAC4 mediates development of hypertension via
vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol 302:
H1894–H1904
112. Choi SY, Ryu Y, Kee HJ et al (2015) Tubastatin A suppresses renal fibrosis via regulation of
epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol
72:130–140
113. Ferrari A, Fiorino E, Longo R et al (2017) Attenuation of diet-induced obesity and induction of
white fat browning with a chemical inhibitor of histone deacetylases. Int J Obes (Lond)
41:289–298
114. Choong CJ, Sasaki T, Hayakawa H et al (2016) A novel histone deacetylase 1 and 2 isoformspecific inhibitor alleviates experimental Parkinson’s disease. Neurobiol Aging 37:103–116
115. Conforti F, Davies ER, Calderwood CJ et al (2017) The histone deacetylase inhibitor,
romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget 8:48737–48754
116. Trifunović D, Arango-Gonzalez B, Comitato A et al (2016) HDAC inhibition in the cpfl1
mouse protects degenerating cone photoreceptors in vivo. Hum Mol Genet 25:4462–4472
117. Li Y, Zhao T, Liu B et al (2015) Inhibition of histone deacetylase 6 improves long-term
survival in a lethal septic model. J Trauma Acute Care Surg 78:378–385
118. Pfaller MA, Messer SA, Georgopapadakou N et al (2009) Activity of MGCD290, a Hos2
histone deacetylase inhibitor, in combination with azole antifungals against opportunistic
fungal pathogens. J Clin Microbiol 47:3797–3804
119. Kuchler K, Jenull S, Shivarathri R et al (2016) Fungal KATs/KDACs: a new highway to better
antifungal drugs? PLoS Pathog 12:e1005938
120. Hailu GS, Robaa D, Forgione M et al (2017) Lysine deacetylase inhibitors in parasites: past,
present, and future perspectives. J Med Chem 60:4780–4804
121. Sumanadasa SD, Goodman CD, Lucke AJ et al (2012) Antimalarial activity of the anticancer
histone deacetylase inhibitor SB939. Antimicrob Agents Chemother 56:3849–3856
122. Chua MJ, Arnold MS, Xu W et al (2017) Effect of clinically approved HDAC inhibitors on
Plasmodium, Leishmania and Schistosoma parasite growth. Int J Parasitol Drugs Drug Resist
7:42–50
123. Ontoria JM, Paonessa G, Ponzi S et al (2016) Discovery of a selective series of inhibitors of
Plasmodium falciparum HDACs. ACS Med Chem Lett 7:454–459
124. Heimburg T, Chakrabarti A, Lancelot J et al (2016) Structure-based design and synthesis of
novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis. J Med Chem 59:2423–2435
125. Meyners C, Wolff B, Kleinschek A et al (2017) Perfluorinated hydroxamic acids are potent
and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa. Bioorg Med
Chem Lett 27:1508–1512
Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery
27